26 LANDSDOWNE STREET, CAMBRIDGE, MA
Stockholders Elect Sonja Banks, Alan Ezekowitz, and Colin Hill as Directors
Changes in Board, Management or Compensation
Material disclosure
Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Annual Report to Security Holders
Announces Recent Business Highlights and Financial Results for First Quarter 2026
Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
Investor Presentation
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Definitive Revised Proxy Statement
Schedule 13G - Ownership Report